Tyme Inc., is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
Copyright Nasdaq. Minimum 15 minutes delayed.
April 9, 2018 at 7:45 AM EDT
February 21, 2018 at 8:30 AM EST
January 18, 2018 from 11:30 AM to 1:30 PM PST